Royalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales. Its portfolio spans treatments in areas such as rare diseases, oncology, neuroscience, immunology, hematology, respiratory disease, infectious disease, and diabetes. Royalty Pharma also supports innovation by partnering with biotechnology and pharmaceutical companies, academic institutions, and research organizations across the life sciences sector. Through this model, the company serves as a specialized capital provider in the healthcare market, linking long-term funding needs with recurring revenue streams from commercialized therapies and pipeline assets.
Website110 East 59th Street
New York, NY, 10022
United States
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market capitalization of
Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.
Royalty Pharma has delivered a strong share price run in recent years, which naturally puts fresh attention on what investors are paying for its earnings today. With the stock now around US$58.52, the key issue is how that outcome lines up with the underlying profit engine of its royalty portfolio. Over the last 3 years, Royalty Pharma has returned about 136.3%, which increases the stakes on whether its current earnings base can carry that kind of share price progress. The recent US$7.5...
Blood Cancer United and Royalty Pharma today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
Investors talking about RPRX also mention
What share of all stock conversation is about RPRX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% +0 | 0% +0 | 0% 0 |
Of the messages about RPRX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 80.85% -19.15 | 90.13% +1.44 | ||
| Bearish | — | — | 19.15% +19.15 | 9.87% -1.44 |
Of the messages about RPRX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 100% | 100% | 72.44% | 67.29% | ||
| Technical Analysis | 0% | 0% | 0.79% | 10.28% | ||
| Analysts | 0% | 0% | 11.02% | 11.49% | ||
| Macro | 0% | 0% | 11.02% | 7.11% | ||
| Earnings | 0% | 0% | 0% | 2.95% | ||
| Controversies | 0% | 0% | 4.72% | 0.88% |
Of the messages about RPRX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 93.15% | 28.63% | 30.52% | ||
| Newcomers | 0% | 6.85% | 71.37% | 69.48% |